Background Palbociclib added to endocrine therapy improves progression-free survival in
hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial …

PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced
breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine …

Background Palbociclib administered with endocrine therapy was tolerable when the overall
incidence of toxicities was assessed separately for three PALOMA studies. This study …

PURPOSE The PALLAS study investigated whether the addition of palbociclib, an oral
CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free …

Background The activity of palbociclib as a single agent in advanced breast cancer has not
been extensively studied, with the only available clinical data limited to heavily pretreated …

Background Growth of hormone-receptor–positive breast cancer is dependent on cyclin-
dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 …

PURPOSE About one third of patients with hormone receptor–positive, human epidermal
growth factor receptor 2–negative breast cancer who have residual invasive disease after …

Background The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in
combination with fulvestrant therapy, prolongs progression-free survival among patients with …

Purpose Real-world data are critical to demonstrate the reproducibility of evidence and
external generalizability of randomized clinical trials. Palbociclib is an oral small-molecule …

The purpose of this review is to summarize the background and latest evidence for the use
of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in …